GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » aTyr Pharma Inc (FRA:471A) » Definitions » 3-Year FCF Growth Rate

aTyr Pharma (FRA:471A) 3-Year FCF Growth Rate : 18.80% (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is aTyr Pharma 3-Year FCF Growth Rate?

aTyr Pharma's Free Cash Flow per Share for the three months ended in Mar. 2025 was €-0.17.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 18.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 29.20% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 36.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of aTyr Pharma was 58.50% per year. The lowest was -8.20% per year. And the median was 25.60% per year.


Competitive Comparison of aTyr Pharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, aTyr Pharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


aTyr Pharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, aTyr Pharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where aTyr Pharma's 3-Year FCF Growth Rate falls into.


;
;

aTyr Pharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


aTyr Pharma  (FRA:471A) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


aTyr Pharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of aTyr Pharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


aTyr Pharma Business Description

Traded in Other Exchanges
Address
10240 Sorrento Valley Road, Suite 300, San Diego, CA, USA, 92121
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

aTyr Pharma Headlines

No Headlines